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Although the apolipoprotein E ɛ4-allele (APOE-ε4) is a susceptibility factor for Alzheimer’s 
disease (AD) and dementia with Lewy bodies (DLB), its relationship with imaging and cognitive 
measures across the AD/DLB spectrum remains unexplored.  
METHODS: 
We studied 298 patients (AD=250, DLB=48; 38 autopsy-confirmed; NCT01800214) using 
neuropsychological testing, volumetric MRI, and APOE genotyping to investigate the 
association of APOE-ε4 with hippocampal volume and learning/memory phenotypes, 
irrespective of diagnosis.  
RESULTS: 
Across the AD/DLB spectrum: (1) hippocampal volumes were smaller with increasing APOE-ε4 
dosage (no genotype x diagnosis interaction observed), (2) learning performance as assessed 
by total recall scores was associated with hippocampal volumes only among APOE-ε4 carriers, 
and (3) APOE-ε4 carriers performed worse on long-delay free word recall. 
DISCUSSION: 
These findings provide evidence that APOE-ε4 is linked to hippocampal atrophy and 
learning/memory phenotypes across the AD/DLB spectrum, which could be useful as 
biomarkers of disease progression in therapeutic trials. 
Keywords: APOE; MRI; hippocampus; Alzheimer’s disease; dementia with Lewy bodies; 
learning; memory; endophenotype  
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1. INTRODUCTION 
Pathological hallmarks of AD are extracellular β-amyloid (Aβ) plaques, and intracellular 
neurofibrillary tangles (NFT). DLB is characterized by intraneuronal α-synuclein inclusions of 
Lewy bodies (LBs) and Lewy neurites [1,2]. Clinically, AD and DLB are diagnosed almost 
exclusively using their respective international consensus diagnostic criteria [1,3,4]. While 
clinical criteria are generally adequate for providing an initial diagnosis and to inform use of 
symptomatic therapies, several issues are noteworthy. First, the hallmark proteinopathies of AD 
and DLB frequently coexist, even among patients diagnosed with a single specific form of 
dementia in life [5–7]. Second, clinical diagnoses do not always match with autopsy results, 
often revealing additional incidental co-pathologies, e.g. small vessel disease [8,9]. Third, 
concomitant pathologies contribute to substantial heterogeneity in disease presentation and 
progression [7]. These findings serve to challenge the classic neurodegenerative disease 
distinctions when relying on clinical diagnosis alone. Thus, the identification of common 
genotype-phenotype (endophenotypic) relationships across the AD/DLB spectrum may offer an 
objective approach to address these limitations [10]. Indeed, genotype in combination with 
morphometric measurements derived from structural imaging have emerged as important 
biomarkers in dementia, which have the potential to advance diagnostic accuracy and improve 
therapeutic end-points in disease-modifying trials (including of mixed disease). 
Apolipoprotein E (APOE) is an important gene that may influence the expression of 
dementia across the AD to Parkinson’s disease spectrum (Figure-S1) [11,12]. Human APOE 
has three allelic variants, resulting from two single nucleotide polymorphisms, which differ at 
one or two amino acid positions: ε2 (Cys-112/Cys-158), ε3 (Cys-112/Arg-158), and ε4 (Arg-
112/Arg-158) [13]. APOE-ε4 is a well-recognized susceptibility factor for late-onset AD, while 
APOE-ε2 is considered protective against AD. Recent neuropathological studies demonstrate 
an overrepresentation of APOE-ε4 not only in AD but also α-synucleinopathies, specifically 
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among patients showing LB pathology with coexisting “high-level” AD (mixed AD/DLB) and 
none/“low-level” AD (“pure” DLB, or Parkinson’s disease dementia [PDD]) [11,12]. Additionally, 
the associations between APOE-ε4 and cerebrovascular pathologies, including cerebral small 
vessel disease and amyloid angiopathy, have been reported in AD [14]. Given that APOE-ε4 is 
a shared susceptibility factor across the AD/DLB spectrum, its association with imaging and 
cognitive endophenotypes irrespective of specific clinical diagnosis may clarify its role in shared 
mechanisms of neurodegeneration. 
One important brain structure that can be measured through imaging is the 
hippocampus, which undergoes early neurodegenerative changes in AD, while it is relatively 
preserved early in the course of DLB [1,3,15]. Hippocampal degeneration in DLB is typically 
related to the severity of NFT pathology, possibly via mechanisms similar to AD [16,17]. Deficits 
in learning and memory, which are linked independently to hippocampal integrity and 
neurogenesis, are also common features of both AD and DLB dementias [18]. No study to date 
has assessed the interrelationships among APOE-ε4, hippocampal volumes, and cognition 
across the AD/DLB spectrum.  
Herein, we investigated the hypothesis that APOE-ε4 may be associated with magnetic 
resonance imaging (MRI)-derived hippocampal volumes, learning, and memory performance, 
across the AD/DLB spectrum.  
 
 




 We included 298 participants (AD=250, DLB=48), recruited from the Cognitive 
Neurology and Geriatric Psychiatry clinics and enrolled in the prospective Sunnybrook Dementia 
Study (SDS [19]; ClinicalTrials.gov: NCT01800214) at the Sunnybrook Health Sciences Centre, 
University of Toronto. The details of this study have been previously reported [19]. All 
participants underwent a detailed neurological evaluation, including standardized MRI, 
comprehensive neuropsychological battery [20], and APOE genotyping [21]. Upon recruitment, 
AD was diagnosed using the Neurological and Communicative Disorders and Stroke and the 
Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria [22], while 
DLB was diagnosed using the Third Report of DLB Consortium criteria [1]. All cases were 
retrospectively re-assessed using the current diagnostic criteria for possible/probable AD [3], 
and possible/probable DLB [4]. Probable AD included those with amnestic (N=174) and non-
amnestic (N=16) presentations, while possible AD allowed for the inclusion of those with a high 
burden of white matter hyperintensities (WMHs) of presumed vascular origin (>10 cm3)(N=60) 
[3]. Probable DLB was diagnosed if two or more of the core clinical features of cognitive 
fluctuations, visual hallucinations, parkinsonism, or REM behaviour disorder were present 
(N=32), while possible DLB was diagnosed when only one of these core features was present 
(N=16). Diagnostic consensus was achieved through review by at least two physicians (MM, 
NH, and SEB) with expertise in dementia diagnosis. Neuropathologic confirmation was available 
on 38 patients, assessed using standardized techniques. The study was approved by the 
Sunnybrook Research Ethics Board. All participants (or surrogate caregivers) provided informed 
consent as per the Declaration of Helsinki.  
Details of participant selection and categorization are shown in Figure-1. 
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2.2 MRI Acquisition: 
 MRIs were acquired on a 1.5 T Signa system (GE Healthcare) as per standardized 
protocols compatible with the Alzheimer’s Disease Neuroimaging Initiative (ADNI). We used 
three sets of structural MRI sequences to obtain T1, T2, and proton-density (PD) weighted 
images. T1-weighted images were acquired using an axial three-dimensional spoiled gradient 
echo sequence. PD/T2-weighted images were obtained using an interleaved axial dual-echo 
spin-echo sequence. MRI parameters are provided in Methods-S1. 
 
2.3  MRI Processing: 
 MRIs were processed using the Semi-Automated Brain Region Extraction and Lesion 
Explorer processing pipeline (SABRE-LE, http://imaging.brainlab.ca), as published previously 
[23,24]. Briefly, a tri-featured approach using T1, T2, and PD-weighted images was employed to 
extract the supratentorial total intracranial volume (sTIV), followed by volumetric quantification of 
cerebrospinal fluid (CSF), white matter (WM), and gray matter (GM) [24] (Methods-S1). To 
compare the general atrophy patterns in AD versus DLB, the volumes for the following regions-
of-interest were also obtained: whole brain (WM+GM), ventricular CSF, and GM of the frontal, 
parietal, occipital, and temporal lobes. Visual inspection with appropriate manual interventions 
was implemented by trained operators to ensure accuracy. Processed skull-stripped T1-
weighted MRIs were carried forward for all further segmentations.  
 
2.4 Hippocampal Segmentation: 
  Hippocampal volumes were obtained using an automated, multi-atlas segmentation 
procedure, validated on our representative hospital-based SDS sample with cross-validation in 
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the widely-available ADNI-1, demonstrating excellent inter/intra-rater reliabilities (Methods-S1) 
[25]. Briefly, each participant’s processed T1-weighted MRI was matched to a multi-atlas 
template library. A voxel-wise voting strategy was applied to combine the best templates into the 
target image space, followed by template-to-target registration, label mapping, and hippocampal 
segmentation [25]. Normalized hippocampal volume ratios (HVa) were calculated as: [(raw 
hippocampal volume/sTIV)×106]. 
 
2.5 White Matter Hyperintensity Quantification: 
WMHs on MRI are radiological markers of cerebral small vessel disease, which 
contribute to significant cognitive decline [26]. We quantified global WMH volumes to assess 
their confounding influence on HVa, using PD/T2-weighted images [24]. Several quality control 
procedures were completed to minimize false-positive classifications, including manual checks 
by trained operators. Normalized WMH volume ratios (WMHa) were calculated as: [(raw WMH 
volume/sTIV)×106]. 
 
2.6 Neuropsychological Assessments: 
 Neuropsychological tests were administered within three months of MRI acquisitions. 
The following evaluations were administered as part of a comprehensive battery: 1) Mini-Mental 
State Examination (MMSE) as a global measure of cognitive function [27], 2) Mattis Dementia 
Rating Scale (DRS) for dementia severity [28], and 3) California Verbal Learning Test (CVLT) 
for episodic verbal learning and memory performance [29]. We used total recall learning scores, 
and long-delay and short-delay recalls of CVLT (details provided in Methods-S1). The DRS-
memory subscore was included as an additional measure of global memory function. Trained 
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psychometrists blinded to neuroimaging, diagnosis, and genotype administered all 
assessments. 
 
2.7 Neuropathology:  
AD was neuropathologically assessed using tau (AT8) and Aβ immunohistochemistry via 
the National Institute of Aging–Reagan guidelines, which incorporates NFT staging [2]. LB 
pathology was documented and staged using α-synuclein immunohistochemistry via the Third 
Report of DLB Consortium, as either amygdala, brainstem, limbic, or diffuse neocortical type [1]. 
Mesial temporal sclerosis was determined on hematoxylin-eosin/Luxol-fast-blue (H&E/LFB) 
staining. Table-S1 lists further details on immunostaining. 
 
2.8  Statistical Analysis: 
 Participants were categorized by APOE-ε4 dose into non-carriers (ɛ4−/−), heterozygotes 
(ɛ4+/−), and homozygotes (ɛ4+/+). Demographic and clinical data were compared using one-
way ANOVA for normally-distributed data, or Kruskal-Wallis H test (H) for non-parametric 
distributions. Categorical data were analyzed using chi-squared (χ2) or Fisher’s Exact tests. The 
atrophy patterns in AD versus DLB were compared using ANOVA, adjusting for age at scan, 
sex, sTIV, formal education, and dementia severity (DRS total score). 
To test the association between APOE-ε4 dose (independent variable) and HVa 
(dependent variable) in the pooled cohort of AD and DLB patients, we used multiple linear 
regressions adjusting for clinical diagnosis, age at scan, and formal education (Model-1) 
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(Methods-S1). The dose-dependent relationship of APOE-ε4 on HVa was modeled by treating 
APOE-ε4 as a numeric continuous variable (i.e., 0, 1, or 2 ε4 alleles).  
To assess whether the association of APOE-ε4 with HVa was stable across the 
diagnostic categories, we tested an interaction between APOE-ε4 dose and clinical diagnosis. If 
the interaction was non-significant, it was removed from the models to interpret the main effects. 
Subsequently, the following sensitivity analyses were performed: 1) further adjusting the model 
for sex and WMHa (Model-2), 2) repeating the analyses after excluding APOE-ε2-carriers due to 
APOE-ε2’s protective influence against AD, 3) separately evaluating the association within the 
AD and DLB samples, and 4) evaluating the GM volumes of frontal, parietal, occipital, and 
temporal lobes across the AD/DLB spectrum to determine the specificity of our findings to the 
hippocampus. 
To assess whether HVa differ in its association with CVLT total recall scores based on 
APOE-ε4 status, hierarchical multiple linear regressions were performed separately among 
APOE-ε4-carriers (ɛ4+) and non-carriers (ɛ4–). In step-1, a block of variables known to influence 
learning ability (i.e., age at scan, formal education, and DRS total score) were first entered, 
followed by HVa in step-2. This analysis was repeated in AD and DLB stratified groups. As other 
CVLT and DRS-memory indices failed to meet linear model assumptions, Mann-Whitney U-
tests were employed to compare performance in ɛ4+ versus ɛ4–. 
Finally, while restricting the sample to those with pathological confirmation, we tested the 
association between APOE-ε4 and antemortem HVa using multiple linear regressions, adjusting 
for pathology-based groups (defined as per [1]), age at scan, and formal education. 
All analyses were performed in SPSS (V22.0, IBM). As our analyses were pre-planned, 
informed by scientific literature, and the cognitive variables are inter-related, statistical 
significance was maintained at P<0.05, two-sided. 
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3. RESULTS 
3.1 Demographic, Clinical, and Neuroimaging Characteristics: 
 Of the 298 participants (48% men, 52% women), 124 were ɛ4–/–, 133 ɛ4+/–, and 41 
ɛ4+/+, including 8 ɛ2/4 and 13 ɛ2/3 cases. Demographic and clinical characteristics were not 
different among these groups (Table-1).  
 The DLB group had a higher male prevalence versus female (67% vs. 33%), while the 
AD group had a higher female prevalence (56% vs. 44%)(χ21,298=8.00, P=0.0047), as consistent 
with the existing literature [11] (Table-S2). No statistically-significant differences were present in 
other demographic and clinical variables analyzed between AD and DLB. APOE genotype 
frequencies in AD and DLB were in Hardy-Weinberg equilibrium.  
 Compared to AD, the DLB group showed less ventricular CSF volume (P=0.0198), and 
relative preservation of the whole brain (P=0.0011) and temporal GM volume (P=0.0065) 
(Figure-S2). These patterns are in line with the general atrophy profiles of AD and DLB patients 
[30]. 
 
3.2  Hippocampal Volumes: 
 The left and right HVa were highly correlated (Pearson’s r=0.79, P<0.0001). Thus, 
bilateral HVa were assessed in all analyses. Table-2 presents the normalized volumetric data.  
In Model-1, APOE-ε4 dose and age at scan emerged as significant predictors of HVa 
(Table-3). APOE-ε4 was inversely related to HVa in a dose-dependent manner: genotype ɛ4+/+ 
was associated with smaller, ɛ4+/– with intermediate, and ɛ4–/– with larger HVa, on average 
(β=-0.20, P<0.0001). No interaction between APOE dosage and clinical diagnosis was observed 
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(P=0.9422), suggesting that the association of APOE-ε4 on HVa was stable across the AD/DLB 
spectrum. Age at scan was inversely (β=-0.42, P<0.0001) related to HVa. 
In models stratified for clinical diagnosis, APOE-ε4 was also inversely associated with 
HVa within the AD (β=-0.20, P=0.0006) and DLB (β=-0.28, P=0.0428) subgroups in a dose-
dependent fashion (Table-S3; Figure-2). 
The dose-dependent association of APOE-ε4 with HVa remained unchanged after 
additionally adjusting for sex and WMHa (Model-2, Table-3); as well as in other sensitivity 
analyses performed upon excluding APOE-ε2 carriers (β=-0.20, P<0.0001) or cases with 
genotype ɛ2/4 only (β=-0.21, P<0.0001). No significant association of APOE-ε4 with other GM 
regions-of-interest was observed. 
 
3.3 Learning and Memory Performance: 
  All models in the hierarchical multiple linear regressions showed a statistically significant 
overall fit for the data (Table-4). In the pooled analysis, after including age at scan, formal 
education and DRS scores, the inclusion of HVa into the regression contributed significantly to 
the model in ɛ4+, but not ɛ4– subgroups. Specifically, HVa associated significantly with CVLT 
total recall performance accounting for an additional 3% of variance in scores among ɛ4+, while 
the relationship was non-significant among those who were ɛ4–.  
  This analysis within the AD and DLB stratified groups was confirmatory, where the 
inclusion of HVa contributed significantly to the models only in AD ɛ4+ and DLB ɛ4+ subgroups 
(but not in AD ɛ4– and DLB ɛ4–) explaining additional variances in CVLT total recall scores.  
  The ɛ4+ individuals performed more poorly on DRS-memory and CVLT long-delay recall 
measures. The CVLT long-delay (20-minute) free recall performance was significantly worse in 
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ɛ4+ versus ɛ4– across all participants (U256=6715.0, P=0.0320) (Table-S4). The DRS-memory 
findings serve as additional validation of the CVLT results. 
 
3.4  Neuropathology: 
 Of the 38 patients with neuropathological examination, 25 were clinically-diagnosed as 
AD (8 possible/17 probable) and 13 as DLB (5 possible/8 probable). All AD cases were 
pathologically confirmed to have AD upon autopsy (Braak: 1 I/II, 7 III/IV, 17 V/VI), including 4 
cases with coexisting LBs (2 as diffuse, 1 amygdala, 1 brainstem only). All DLB cases had LB 
pathology upon autopsy (12 as diffuse, 1 limbic), with varying degrees of concomitant NFT 
pathology (Braak: 2 I/II, 4 III/IV, 7 V/VI). Demographic data, antemortem HVa, and details of 
each pathology-confirmed case are provided (Table-S5; Table-S6). 
In our pathology-confirmed sub-sample, the ɛ4+ showed smaller antemortem HVa 
versus ɛ4– (β=-0.32, P=0.0495), with non-significant interaction between APOE-ɛ4 × pathology-
defined groups (P=0.2616) (Table-S7). When analyzed based on APOE-ε4 dose, a trend-level 
relationship was observed (β=-0.29, P=0.0839). The antemortem HVa correlated with post-
mortem Braak NFT stages (Spearman’s ρ=-0.32, P=0.0476) (Figure-S4). 
 
4. DISCUSSION 
 We found that across the AD/DLB dementia spectrum: 1) APOE-ε4 was associated with 
smaller hippocampal volumes in a dose-dependent manner, 2) global learning performance was 
uniquely related to hippocampal volumes among ɛ4+ but not ɛ4– individuals, and 3) the ɛ4+ 
participants were significantly impaired on long-delay free recall of words. The APOE-ε4 dose 
 
14 of 38 
 
was also inversely related to hippocampal volumes in the AD and DLB subgroups. Likewise, 
global learning performance was associated with hippocampal volumes only among the ε4+ of 
AD and DLB but not among the respective ε4– individuals. Furthermore, we found an inverse 
relationship between APOE-ε4 dosage and hippocampal volumes in our pathology-confirmed 
sub-sample. 
 A prior study using ADNI-1 data has reported an association between APOE-ε4 and 
smaller hippocampal volumes in AD [31], although there are contradictory reports [32–34]. 
ADNI-1 is a multi-centre clinical trial population representing relatively well-educated and 
comorbidity-free individuals, which may limit the generalizability of those results. To our 
knowledge, no study has explored an association of APOE-ε4 with hippocampal volumes in 
DLB, or across the AD/DLB spectrum including quantification of small vessel disease, or has 
examined this relationship using pathology-confirmed cases. This is important, given the 
frequent occurrence of mixed pathologies not only in the clinic but also community-based 
samples [9,35]. We incorporated all cases meeting the clinical diagnostic criteria for AD or DLB, 
irrespective of the extent of small vessel disease on MRI, knowing that several cases will also 
have mixed AD/DLB on autopsy; indeed, we showed this to be the case in our autopsy-
confirmed sub-sample. Compared to ADNI, we have previously shown our sample to be more 
generalizable than ADNI to the real world where co-pathologies such as white matter disease 
are highly prevalent [36]. 
We demonstrate that this association appears to be stable across the AD/DLB spectrum 
as well as in the AD and DLB groups, irrespective of the specific clinical diagnosis. We found 
support for this finding by systematically adjusting for pertinent confounders including WMHs, 
which can independently impact hippocampal volumes directly, or indirectly via vascular 
damage [19,37]. Although the precise mechanisms remain unclear, it is likely that APOE’s 
allele-specific structural and biochemical properties play a significant role. Two types of 
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mechanisms for APOE have been highlighted using animal and in vitro investigations, with 
supportive evidence accumulating from human studies: Aβ-dependent and Aβ-independent 
mechanisms. These mechanisms reflect altered properties for APOE-ε4 compared to the 
APOE-ε3 and APOE-ε2 alleles [13], which may be operational across the AD/DLB spectrum, as 
discussed below. 
The Aβ-dependent mechanisms postulate increased deposition and impaired clearance 
of Aβ in ɛ4+, as shown in mouse models expressing human APOE-ε4 [38]. This hypothesis is 
supported in humans, with findings of more extensive Aβ deposition in ɛ4+ of AD in 
temporoparietal regions, as detected by Pittsburgh Compound-B (PIB) [39]. Similarly, a 
significantly lower CSF level of Aβ-42, an indirect measure of increased cerebral retention, is 
demonstrated in AD ɛ4+ [40]. Patients clinically-diagnosed with DLB are also commonly PIB-
positive (~60%), and elevated Aβ deposition in the cortex is reported in ɛ4+ across the LB 
disease spectrum [41]. Such augmented APOE-ε4-associated Aβ deposition in the brain 
including neocortical regions can disrupt cortico-hippocampal networks and may indirectly lead 
to hippocampal atrophy via cortical denervation. In fact, an association between elevated Aβ 
deposition and smaller hippocampal volumes has been reported with modulatory effects on 
episodic memory in AD [42]. This sequential progression of events, from Aβ deposition to 
hippocampal atrophy to memory dysfunction, may be exacerbated in the context of much 
heavier Aβ burden in ɛ4+ of AD and DLB. Hence, such APOE-ε4-associated hippocampal loss 
as observed in our study, along with greater impairment in delayed memory recall, could have 
been predicted. 
Hypothesized Aβ-independent mechanisms include an increased tendency of APOE-ε4 
to induce tau hyperphosphorylation and undergo proteolysis, leading to ineffective repair 
capacity, cytoskeletal abnormalities, and mitochondrial energy disruptions [13,43]. Tau 
hyperphosphorylation and accumulation of C-terminal truncated fragments have been detected 
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in the hippocampus of transgenic mice expressing human APOE-ε4 [44]. Likewise in humans, 
greater levels of hyperphosphorylated tau, along with lower expression of proteins associated 
with neuronal transport and synaptic health were observed in post-mortem hippocampal tissues 
from APOE-ε4-homozygous versus APOE-ε3-homozygous AD patients [45]. Such functional 
abnormalities can adversely impact synaptodendritic health, especially in highly dynamic 
structures like the hippocampus, which undergoes extensive neuroplastic changes crucial to its 
role in learning/memory [13,45]. Indeed, healthy ɛ4+ individuals show abnormal task-based 
activation and resting-state connectivity patterns, as well as impaired glucose metabolism in the 
hippocampus [46,47]. Hence, hippocampal volume loss associated with APOE-ε4 may also be a 
consequence of functional abnormalities in neuronal metabolism and synaptodendritic 
maintenance, commencing decades before clinically-overt dementia.  
As AD pathology frequently coexists with LB pathology [5,35], it is possible that APOE-
ε4 may contribute to hippocampal degeneration in DLB cases by exacerbating AD-type 
tauopathy. In fact, the odds of carrying APOE-ε4 also progressively decrease across the AD to 
LB disease spectrum [11], much like the severity of tauopathy. Previous work by Kantarci and 
colleagues have found antemortem hippocampal volumes to decrease from high to intermediate 
to low “likelihood” of DLB, as per the Third Report of DLB Consortium scheme [16]. Moreover, 
like AD, antemortem hippocampal volumes in DLB relate to the severity of NFT pathology 
[16,17]. These observations are consistent with our pathology data. Thus, the APOE-ε4 isoform 
may affect hippocampal volume by aggravating or independently instigating tauopathy across 
the AD/DLB spectrum, perhaps via modulation of tau hyperphosphorylation. Future work 
incorporating multimodal indices that correlate with AD-type patterns (e.g., SPARE-AD [49,50]) 
would be exciting avenues to explore these hypotheses. 
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The estimates obtained for the association of APOE-ε4 with antemortem hippocampal 
volume in our relatively small pathology-confirmed sub-sample were comparable to those of our 
clinical sample, suggesting a well-characterized cohort. APOE-ε4 has also been associated with 
poor prognosis in DLB, especially in those with smaller hippocampal volumes [48]. Altogether, 
these observations suggest an important link between APOE-ε4 and hippocampal degeneration 
across the AD/DLB spectrum. While DLB is characterized by relative preservation of the medial 
temporal lobe (MTL) structures on MRI versus AD in early stages, several DLB patients may 
present with hippocampal/MTL atrophy, as observed in our study. Given the immense relevance 
of this observation in clinical and research settings and for patient recruitment in clinical trials, 
further characterization of this heterogeneity in DLB cases is desirable, as we move closer to 
precision medicine approaches.  
Some evidence links AD and LB pathologies together, suggesting possible synergistic 
interactions among tau, Aβ, and α-synuclein in promoting fibrillization and subsequent 
neurodegeneration, especially in mixed dementia. For example, α-synuclein and tau co-
fibrillization in LB aggregates have been observed [51]. Likewise, enhanced accumulation of α-
synuclein associated with Aβ in animal models, as well as increased coexistence of α-synuclein 
lesions in human brains with Aβ deposits (versus those without) have been reported [52,53]. 
This suggests that in ɛ4+, exacerbation of Aβ burden and/or tauopathy may also impact α-
synuclein aggregation, contributing to hippocampal loss in the context of mixed disease (Figure-
S5).  
APOE-ɛ4 may also have distinct roles in α-synuclein aggregation [54], and the 
underlying mechanisms may be different from AD-type proteinopathies. A more extensive 
pattern of atrophy associated with APOE-ɛ4 in regions beyond the hippocampus in DLB/PDD 
and in “mixed” versus “pure” DLB cases may highlight such mechanisms in the context of pure 
α-synucleinopathies. This approach may ideally be pursued in the future using voxel-based 
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morphometry which allows for the elucidation of focal anatomical changes irrespective of 
predefined regional or structural boundaries. 
We also found the association of hippocampal volumes with global learning performance 
uniquely among ɛ4+ in the overall sample, and in AD and DLB subgroups. This reinforces 
APOE-ε4’s involvement as an important moderating factor in hippocampal degeneration across 
the AD/DLB spectrum with measurable cognitive effects among ɛ4+ carriers. Such association 
was not observed among ɛ4–, indicating that other factors are probably more important in these 
individuals in determining hippocampal and associated cognitive phenotypes. Learning deficits 
in ɛ4+ have previously been reported in both human and animal studies [13,55]. Recently, a 
large study confirmed learning impairments in ɛ4+ of Parkinson’s disease and Parkinson’s 
disease dementia [56]; however, unlike the current study, specific associations with 
hippocampal volumes were not investigated.  
Finally, patients with ɛ4+ also performed poorly on delayed recall measures in our 
pooled sample, as consistent with the previous AD and PDD literature [55,56]. Indeed, learning 
and memory also depend upon hippocampal synaptodendritic plasticity, constant neurogenesis, 
and communications within the brain’s memory networks. It is thus conceivable that APOE-ε4 
may contribute to cognitive deficits secondary to injury to these pathways, including 
hippocampal degeneration. 
 The strengths of our study include a well-characterized cohort, validated through 
standardized instruments and expert consensus, pathological confirmation in a subset of 
patients demonstrating a high degree of concordance between clinical and post-mortem 
diagnoses, rigorous image-processing methods including a hippocampal segmentation scheme 
validated specifically for older adults and mixed dementia applications, and adjustments for 
pertinent confounders including WMH volumes.  
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There are certain limitations. First, as this was a cross-sectional study, causal inferences 
could not be drawn. Second, concomitant AD-type pathology is common in clinically-diagnosed 
DLB, and even evident in cognitively-normal elderly and “pure” DLB [57]. Given that “pure” DLB 
cases are relatively uncommon as consistent with our pathology data and were 
underrepresented in our study, results should be extended to these cases with caution. Third, 
the pathology of transactive response DNA-binding protein-43 (TDP-43) is known to influence 
cognitive and hippocampal phenotypes [6]. As only a few participants (N=13) underwent TDP-
43 immunohistochemistry, its influence on our results could not be assessed. Finally, our DLB 
group was limited by a relatively small sample-size, although comparable to other single-
centered investigations [58–60]. This nevertheless prevented us from analyzing cognitive 
differences within the DLB group in detail (i.e., CVLT long- and short-delay recalls). Likewise, 
our pathology-confirmed sample was also small, precluding us from examining relationships 
separately within the pathology-defined groups. Therefore, it is important to validate our findings 
in studies such as ONDRI and CCNA, which are examining patients covering the full spectrum 
of neurodegenerative diseases using a comprehensive and standardized research platform. 
 
4.1 Conclusions: 
Our study identifies hippocampal volume and performance in learning/memory as 
important endophenotypes of APOE-ε4 across the AD/DLB spectrum. A subset of these 
patients may be candidates for therapeutic interventions targeting APOE-ε4 using hippocampal 
volume as an outcome measure. If APOE-ε4 indeed operates through similar mechanisms, 
interventions that prevent hippocampal neurodegeneration or stimulate neurogenesis in AD ɛ4+ 
(e.g. exercise [61]) may also be beneficial for DLB ɛ4+ cases. Slowing of this disproportionate 
degeneration could be a viable end-point in clinical trials, to facilitate precision medicine 
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approaches in the future, especially for late-onset sporadic forms of dementia, which often 
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6. FIGURE CAPTIONS 
 
Figure 1: Flowchart of participant selection and categorization. 
Abbreviations: AD, Alzheimer’s disease; APOE, apolipoprotein E; DLB, dementia with Lewy 
bodies; ɛ4+, carriers of at least one APOE-ε4 allele; ɛ4– or ɛ4−/−, APOE-ε4 non-carriers; ɛ4+/+, 
APOE-ε4 homozygotes; ɛ4+/−, APOE-ε4 heterozygotes. 
 
Figure 2: The association of APOE-ɛ4 with hippocampal volumes across the spectrum of AD 
and DLB. 
Boxplots presenting the normalized hippocampal volume ratios for the pooled sample of AD and 
DLB (A), and within the clinical diagnostic categories of AD and DLB (B), along with P-values 
showing significant relationships. The AD/DLB spectrum can be conceptualized as representing 
a continuum, with amyloidopathy and tauopathy at one extreme and α-synucleinopathy at the 
other extreme, with varying degrees of the three proteinopathies in the middle (C). APOE-ɛ4 has 
been identified as a risk factor across this spectrum [11]. Our study identifies a link between 
APOE-ɛ4 and hippocampal volumes in AD, DLB, as well as across the AD/DLB spectrum. 
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Clinical diagnosis of AD or DLB. Availability of sufficient-quality 
MRI and APOE genotype. 
Exclusion: 
 
History of head trauma or psychoactive substance abuse, 
hydrocephalus, neoplasm, and/or unrelated neurological or 
psychiatric disorders that typically interfere with cognitive 
functions. Leukoariosis, microbleeds, focal lesions, or lacunes 
on MRI were not exclusionary. 
 
N = 309 
 
 
Clinically-diagnosed AD or DLB 
 




(60 possible/190 probable) 
 
N = 250 
 
DLB 
(16 possible/32 probable) 
 









N = 298 
ɛ4− 
 
N = 16 
ɛ4+ 
 
N = 22 
ɛ4 +/− 
 
N = 133 
ɛ4 +/+ 
 
N = 41 
Secondary screening (excluded) 
 
Overt strokes (N = 11) 
ɛ4 −/− 
 
N = 124 
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Table 1. Demographic and general clinical characteristics by APOE groups. 
 




[N = 124] 
ɛ4 +/– 
[N = 133] 
ɛ4 +/+ 
[N = 41] 
P value 
     
Age, mean (SD), y     
At onset 68.5 (9.8) 66.6 (10.9) 66.2 (8.4) 0.24 ¶ 
At scan 72.5 (9.4) 71.2 (8.9) 69.9 (7.9) 0.22 ¶ 
Disease duration, mean (SD), y 4.0 (2.7) 4.6 (6.0) 3.7 (2.2) 0.63 ‡ 
Sex, No. (%)     
Male 64 (52) 61 (46) 18 (44) 
0.56 § 
Female 60 (48) 72 (54) 23 (56) 
Formal education, mean (SD), y 14.0 (3.6) 14.0 (3.6) 13.0 (3.8) 0.24 ¶ 
MMSE total, mean (SD) * 23.5 (4.3) 23.7 (3.8) 22.6 (5.5) 0.37 ¶ 
DRS total, mean (SD) † 118.3 (14.7) 118.3 (12.8) 120.0 (12.1) 0.78 ¶ 
Clinical diagnosis, No. (%)     
AD 103 (83) 113 (85) 34 (83) 
0.90 § 
DLB 21 (17) 20 (15) 7 (17) 
     
 
Abbreviations: AD, Alzheimer’s disease; APOE, apolipoprotein E; DLB, dementia with Lewy bodies; 
DRS, dementia rating scale; MMSE, mini-mental status examination; * Score out of 30; † Score out 
of 144; ‡ Kruskal-Wallis H test; § Chi-squared test; ¶ One-way ANOVA. 
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Table 2. The volumetric data for hippocampal volumes and white matter hyperintensities by APOE genotype. 
 
 APOE genotype 
Characteristics ɛ4 –/–  ɛ4 +/–  ɛ4 +/+  ɛ3/3  ɛ3/4  
      
HVa, mean (SD) 4054.0 (635.0) 3926.4 (559.4) 3778.9 (660.2) 4029.2 (627.1) 3906.8 (547.8) 
AD 4053.8 (651.3) 3904.0 (583.5) 3803.3 (668.5) 4023.5 (640.4) 3883.6 (566.9) 
DLB 4054.6 (562.4) 4045.8 (375.3) 3660.2 (654.4) 4055.3 (577.0) 4044.3 (402.7) 
WMHa, median (IQR) 3289.6 (6848.5) 3616.1 (7583.3) 2305.3 (5371.0) 3652.2 (7604.3) 3434.0 (7218.5) 
AD 3403.4 (7653.4) 3434.0 (7218.5) 1984.7 (6419.6) 3670.3 (7665.0) 3434.0 (7156.8) 
DLB 3104.6 (6624.1) 3899.6 (11208.9) 2827.2 (2101.9) 3173.0 (6898.7) 3343.1 (9234.3) 
      
 
Abbreviations: APOE, apolipoprotein E; HVa, normalized hippocampal volume ratios (×106); IQR, interquartile range; SD, standard 
deviation; WMHa, normalized white matter hyperintensities volume ratios (×106). 
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Table 3. Multiple linear regressions presenting effects of independent variables on hippocampal volume: APOE-ε4 dose-dependent models. 
 
APOE-ε4 was treated as a continuous variable to assess dose-dependency. Unstandardized coefficients (b) with 95% confidence intervals 
(CI), standardized coefficients (β), and P values are presented, along with each model’s R-squared statistic.  
 HVa, difference 
Predictors 
Model 1†  Model 2† 
b  95% CI β P value  b 95% CI β P value 
          
APOE-ɛ4 dose  -176.64 -268.52, -84.76 -0.20 < 0.0001  -180.44 -272.37, -88.51 -0.20 < 0.0001 
Clinical diagnosis (DLB)  41.15 -130.13, 212.43  0.03    0.64   64.86 -108.91, 238.63  0.04    0.46 
Age at scan, y -28.22 -35.27, -21.17 -0.42 < 0.0001  -26.30 -34.10, -18.51 -0.39 < 0.0001 
Formal education, y -12.14 -29.53, 5.25 -0.07    0.17  -11.65 -29.05, 5.75 -0.07    0.19 
Sex (females)  –     87.22 -42.53, 216.98  0.07    0.19 
WMHa *  –    -69.43 -182.99, 44.13 -0.07    0.23 
          
R squared 0.197  0.204 
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Abbreviations: APOE, apolipoprotein E; HVa, normalized hippocampal volume ratios (×106); WMHa, normalized white matter 
hyperintensities volume ratios (×106); * log-transformed values were analyzed; † APOE-ɛ4 dose × clinical diagnosis interaction was non-
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Boxplots presenting the normalized hippocampal volume ratios for the pooled sample of AD and DLB (A), and within the clinical diagnostic 
categories of AD and DLB (B), along with P-values showing significant relationships. The AD/DLB spectrum can be conceptualized as 
representing a continuum, with amyloidopathy and tauopathy at one extreme and α-synucleinopathy at the other extreme, with varying 
degrees of the three proteinopathies in the middle (C). APOE-ɛ4 has been identified as a risk factor across this spectrum [11]. Our study 
identifies a link between APOE-ɛ4 and hippocampal volumes in AD, DLB, as well as across the AD/DLB spectrum. 
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Table 4. Hierarchical multiple linear regressions relating CVLT total recall scores with hippocampal 
volume in ɛ4+ versus ɛ4–. 
Total ɛ4+ [N = 158]  ɛ4– [N = 110] 
 Step 1 Step 2  Step 1 Step 2 
      
Age at scan  -0.15 *  -0.10   -0.06   0.01 
Formal education   0.05   0.07   -0.02   -0.01 
DRS total   0.61 †   0.59 †    0.61 †   0.60 † 
HVa     –   0.17 *      –   0.14 
R squared   0.42   0.45 ‡    0.37   0.38 
      
AD ɛ4+ [N = 133]  ɛ4– [N = 92] 
 Step 1  Step 2   Step 1 Step 2 
      
Age at scan  -0.16 *  -0.11   -0.08  -0.01 
Formal education   0.02   0.04    0.01   0.02 
DRS total   0.61 †   0.59 †    0.58 †   0.57 † 
HVa     –   0.16 *      –   0.15 
R squared   0.41   0.43 ‡    0.34   0.35 
      
DLB ɛ4+ [N = 25]  ɛ4– [N = 18] 
 Step 1  Step 2   Step 1 Step 2 
      
Age at scan  -0.06  -0.01   -0.05  -0.05 
Formal education   0.26   0.36 *   -0.18  -0.18 
DRS total   0.55 *   0.40 *    0.84 †   0.84 † 
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Standardized beta (β) are presented, unless otherwise stated. In Step 1, age at scan, formal 
education, and DRS total score variables were entered, followed by HVa in Step 2.  
Abbreviations: AD, Alzheimer’s disease; APOE, apolipoprotein E; CVLT, California verbal learning 
test; DLB, dementia with Lewy bodies; DRS, dementia rating scale; HVa, normalized hippocampal 
volume ratios (×106); ɛ4+, carriers of at least one APOE-ε4 allele; ɛ4–, APOE-ε4 non-carriers. 
* P < 0.05; † P < 0.001; ‡ Statistically-significant F change (versus model 1) at P < 0.05.  
HVa     –   0.35 *      –  -0.01 
R squared   0.50   0.60 ‡    0.72   0.72 
      
